The data shows a consistent upward trend in the import of penicillins or streptomycins in dosage forms to Germany, rising steadily from $159.43 million in 2024 to $168.53 million by 2028. Although specific figures for 2023 are not given, the consistent increase suggests a healthy demand and a stable growth trend in this market sector.

Year-on-year percentage increases are modest, reflecting a gradual but steady market expansion. Analyzing a 5-year period, the compound annual growth rate (CAGR) signifies a stable growth trajectory without sudden peaks or troughs, indicative of predictable market prospects and sustained demand.

Future trends to watch for include:

Impact of new regulatory changes in the pharmaceutical industry in the EU.
Growth in the healthcare sector, particularly in generic drug usage.
Potential technological advancements in drug formulation and delivery impacting imports.